Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Houvras

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The Journal of Biological Chemistry|August 18, 2000
BRCA1 physically and functionally interacts with ATF1Y Houvras, M Benezra, H Zhang, et al.
Nature|September 20, 1997
Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1K Somasundaram, H Zhang, Y X Zeng, et al.
The Journal of Clinical Endocrinology and Metabolism|April 17, 2013
Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trialR C Smallridge, J A Copland, M S Brose, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2022
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trialF Griesinger, G Curigliano, M Thomas, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The Journal of Biological Chemistry|August 18, 2000
BRCA1 physically and functionally interacts with ATF1Y Houvras, M Benezra, H Zhang, et al.
Nature|September 20, 1997
Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1K Somasundaram, H Zhang, Y X Zeng, et al.
The Journal of Clinical Endocrinology and Metabolism|April 17, 2013
Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trialR C Smallridge, J A Copland, M S Brose, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2022
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trialF Griesinger, G Curigliano, M Thomas, et al.
Pageof 1